Lütfiye ÖZPAK, Murat ŞAHİN, İbrahim Seyfettin ÇELİK, Bekir Mehmet KELLECİ, Mustafa ÇELİK
{"title":"2型糖尿病患者痴呆生物标志物的水平","authors":"Lütfiye ÖZPAK, Murat ŞAHİN, İbrahim Seyfettin ÇELİK, Bekir Mehmet KELLECİ, Mustafa ÇELİK","doi":"10.17826/cumj.1311596","DOIUrl":null,"url":null,"abstract":"Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes.
 Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples.
 Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels.
 Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.","PeriodicalId":10748,"journal":{"name":"Cukurova Medical Journal","volume":"26 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The level of dementia biomarkers in type 2 diabetes mellitus\",\"authors\":\"Lütfiye ÖZPAK, Murat ŞAHİN, İbrahim Seyfettin ÇELİK, Bekir Mehmet KELLECİ, Mustafa ÇELİK\",\"doi\":\"10.17826/cumj.1311596\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes.
 Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples.
 Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels.
 Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.\",\"PeriodicalId\":10748,\"journal\":{\"name\":\"Cukurova Medical Journal\",\"volume\":\"26 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cukurova Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17826/cumj.1311596\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cukurova Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17826/cumj.1311596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The level of dementia biomarkers in type 2 diabetes mellitus
Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes.
Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples.
Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels.
Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.